A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lee, Sujin ^a,b   Nguyen, Minh Trang ^a,b   Currier, Michael G ^a,b   Jenkins, Joe B ^c   Strobert, Elizabeth A ^c   Kajon, Adriana E ^d   Madan Lala, Ranjna ^e   Bochkov, Yury A ^f   Gern, James E ^f   Roy, Krishnendu ^e   Lu, Xiaoyan ^g   Erdman, Dean D ^g   Spearman, Paul ^a,b   Moore, Martin L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c EMORY UNIVERSITY   (United States)

^d LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^e GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; POLYVALENT INACTIVATED HUMAN RHINOVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY; ANTIGEN; HYPOTHESIS TESTING; INFECTIOUS DISEASE; PRIMATE; VACCINE; VIRUS;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NATURAL SCIENCE; NONHUMAN; RHESUS MONKEY; VACCINATION; VACCINE PRODUCTION;

HUMAN RHINOVIRUS SP.; MACACA MULATTA; MUS; RHINOVIRUS;

EID: 84988710060     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12838     Document Type: Article

References (38)

1. Gwaltney, Jr. J.M., Hendley, J. O., Simon, G., & Jordan, Jr. W.S. Rhinovirus infections in an industrial population. I. The occurrence of illness. N. Engl. J. Med. 275, 1261-1268 (1966
2. Glanville, N., & Johnston, S. L. Challenges in developing a cross-serotype rhinovirus vaccine. Curr. Opin. Virol. 11, 83-88 (2015
3. Jain, S., et al. Community-Acquired pneumonia requiring hospitalization among U.S. adults. N. Engl. J. Med. 373, 415-427 (2015
4. Jain, S., et al. Community-Acquired pneumonia requiring hospitalization among U.S. children. N. Engl. J. Med. 372, 835-845 (2015
5. Barclay, W. S., al-Nakib, W., Higgins, P. G., & Tyrrell, D. A. The time course of the humoral immune response to rhinovirus infection. Epidemiol. Infect. 103, 659-669 (1989
6. Doggett, J. E., Bynoe, M. L., & Tyrrell, D. A. Some attempts to produce an experimental vaccine with rhinoviruses. Br. Med. J. 1, 34-36 (1963
7. Mufson, M. A., et al. Effect of neutralizing antibody on experimental rhinovirus infection. JAMA. 186, 578-584 (1963
8. Perkins, J. C., et al. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am. J. Epidemiol. 90, 319-326 (1969
9. Perkins, J. C., et al. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am. J. Epidemiol. 90, 519-526 (1969
10. Buscho, R. F., Perkins, J. C., Knopf, H. L., Kapikian, A. Z., & Chanock, R. M. Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine. J. Immunol. 108, 169-177 (1972
11. Mitchison, D. A. Prevention of colds by vaccination against a rhinovirus: a report by the scientific committee on common cold vaccines. Br. Med. J. 1, 1344-1349 (1965
12. Stott, E. J., Draper, C., Stons, P. B., & Tyrrell, D. A. Absence of heterologous antibody responses in human volunteers after rhinovirus vaccination. (Brief report). Arch. Gesamte. Virusforsch. 28, 89-92 (1969
13. Glanville, N., et al. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. PLoS Pathog. 9, e1003669 (2013
14. Cooney, M. K., Fox, J. P., & Kenny, G. E. Antigenic groupings of 90 rhinovirus serotypes. Infect. Immun. 37, 642-647 (1982
15. McLean, G. R., et al. Rhinovirus infections and immunisation induce crossserotype reactive antibodies to VP1. Antiviral. Res. 95, 193-201 (2012
16. Couch, R. B. The common cold: control? J. Infect. Dis. 150, 167-173 (1984
17. Fox, J. P. Is a rhinovirus vaccine possible? Am. J. Epidemiol. 103, 345-354 (1976
18. Crowe, Jr. J.E. Universal flu vaccines: primum non nocere. Sci. Transl. Med. 5, 200fs234 (2013
19. Vollmers, C., Sit, R. V., Weinstein, J. A., Dekker, C. L., & Quake, S. R. Genetic measurement of memory B-cell recall using antibody repertoire sequencing. Proc. Natl Acad. Sci. USA 110, 13463-13468 (2013
20. McIntyre, C. L., Knowles, N. J., & Simmonds, P. Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types. J. Gen. Virol. 94, 1791-1806 (2013
21. Palmenberg, A. C., et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 324, 55-59 (2009
22. Lee, W. M., et al. Human rhinovirus species and season of infection determine illness severity. Am. J. Respir. Crit. Care. Med. 186, 886-891 (2012
23. Miller, E. K., et al. A novel group of rhinoviruses is associated with asthma hospitalizations. J. Allergy Clin. Immunol. 123, 98-104 e101 (2009
24. Arden, K. E., McErlean, P., Nissen, M. D., Sloots, T. P., & Mackay, I. M. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. J. Med. Virol. 78, 1232-1240 (2006
25. Kistler, A., et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J. Infect. Dis. 196, 817-825 (2007
26. Lamson, D., et al. MassTag polymerase-chain-reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza-like illness in New York State during 2004-2005. J. Infect. Dis. 194, 1398-1402 (2006
27. Renwick, N., et al. A recently identified rhinovirus genotype is associated with severe respiratory-Tract infection in children in Germany. J. Infect. Dis. 196, 1754-1760 (2007
28. Bochkov, Y. A., et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat. Med. 17, 627-632 (2011
29. Bochkov, Y. A., et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc. Natl Acad. Sci. USA 112, 5485-5490 (2015
30. Bartlett, N. W., et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 14, 199-204 (2008
31. Blanco, J. C., et al. Prophylactic antibody treatment and intramuscular immunization reduce infectious human rhinovirus 16 load in the lower respiratory tract of challenged cotton rats. Trials Vaccinol. 3, 52-60 (2014
32. Kim, J. H., Davis, W. G., Sambhara, S., & Jacob, J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl Acad. Sci. USA 109, 13751-13756 (2012
33. Hamory, B. H., Hamparian, V. V., Conant, R. M., & Gwaltney, Jr. J.M. Human responses to two decavalent rhinovirus vaccines. J. Infect. Dis. 132, 623-629 (1975
34. Racaniello, V. R., & Baltimore, D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214, 916-919 (1981
35. Farid, S. S., Washbrook, J., & Titchener-Hooker, N. J. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol. Prog. 21, 486-497 (2005
36. Thomassen, Y. E., et al. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS ONE 8, e83374 (2013
37. Thomassen, Y. E., et al. Scale-down of the inactivated polio vaccine production process. Biotechnol. Bioeng. 110, 1354-1365 (2013
38. Reed, L. J., & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27, 493-497 (1938